{"database":"EGA","file_versions":[],"scores":null,"additional":{"omics_type":["Genomics"],"study_type":["Other"],"full_dataset_link":["https://ega-archive.org/studies/EGAS00001004043"],"host":["EGA"],"description":["EGA study EGAS00001004043"],"dataset_title":["RNAseq sample"],"repository":["EGA"],"category":["restricted"],"name_synonyms":["Thymus-Dependent Lymphocytes, cycline, DmcyclinE, fond, Immunotherapies., cycE, T-Lymphocyte, CycEI, Cyc E, br37, Cell, l(2)br37, CYCLE, cdi7, l(2)k02514, Ccne, DmCycE, cyclinE, BG:DS07108.3, T Lymphocyte, T-Cell, Cdi7, CDI7, CyeE, l(2)05206, immature T cell, T lymphocyte, T-cell, CYCE, l(2)k02602, T-Cells, DmelCG3938, CyclE, Thymus-Dependent, l(2)35Dd, 3938, T, Lymphocytes, DmcycE, Thymus-Dependent Lymphocyte, l(2)k05007, D-CycE, T Cells, dm-cycE, T cell, l35Dd, mature T cell, Cells, T Cell, T Lymphocytes, CG3938, Thymus Dependent Lymphocytes, Lymphocyte"],"description_synonyms":["Subset, Thymus-Dependent Lymphocytes, cycline, DNS, (Deoxyribonucleotide)n, determination, Plasmacytes, DmcyclinE, Blood, fond, Receptors, dominant cleft palate, cycE, T-Lymphocyte, CycEI, l(2)br37, Deoxyribonucleic acids, CYCLE, cdi7, Responder protein Smok-Tcr, Readability, Ccne, cyclinE, T Lymphocyte, Deoxyribonucleic Acid, PBMC, responsivity, Cdi7, CDI7, T Cell Subset, immature T cell, treatment, reactivity, thymus nucleic acid, anatomical systems, CYCE, isolated, T-Cells, DmelCG3938, CyclE, T Cell Antigen Receptor, 3938, T, Double Stranded, T-Cell Subset, Deoxyribonucleic acid, DmcycE, free, T-Cell Receptors, l(2)k05007, T Cells, dm-cycE, Clients, mature T cell, disease management, Therapies, Double-Stranded DNA, liquid, (Deoxyribonucleotide)m, deoxyribonucleic acids, DNAn, Plasma Cell, T Lymphocytes, Thymus Dependent Lymphocytes, Lymphocyte, CPI, Antigen Receptors, Therapy, T-Cell Antigen Receptor, whole blood, T-Cell Receptor, T-Cell Antigen, T-lymphocyte receptor complex, PBMC cell, effector B-cell, DNAn+1, incomplete, Subsets, Double-Stranded, Cyc E, br37, T Lymphocyte Subset, Client, Cell, results, predicted, (Deoxyribonucleotide)n+m, abolished, T Cell Antigen, 2.7.11.1, Antigen Receptor, plasma B cell, l(2)k02514, DmCycE, BG:DS07108.3, TCR complex, T Cell Receptor, T-Cell, chemical analysis, Accomplishments, background, Achievements, CyeE, ds-DNA, l(2)05206, desoxyribose nucleic acid, T Lymphocyte Subsets, T lymphocyte, plasmocyte, T lymphocyte receptor complex, T-Lymphocyte Subset, Plasma, TCR, Tcr, T-Cell Subsets, T-cell, plasma B-cell, l(2)k02602, Peripheral Blood, PBM cell, Thymus-Dependent, l(2)35Dd, effector B cell, Lymphocytes, Understanding, T Cell Subsets, Biopsies., Treatments, introduction, Thymus-Dependent Lymphocyte, SmokTcr, Plasmacyte, Reticuloendothelial System, D-CycE, Accomplishment, T cell, l35Dd, cleft palate, Therapeutic, Patient, T Cell Receptors, plasmacyte, PBMCs, Cells, ds DNA, T-Cell Antigen Receptors, Desoxyribonukleinsaeure, Dominant negative form of Smok, Treatment, T Cell, T-cell receptor complex, Receptor, assay, DNA, response, CG3938, peripheral blood mononuclear cell"],"additional_accession":[]},"is_claimable":false,"name":"Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy","description":"BACKGROUND: Our understanding of T cell evolution under checkpoint inhibitors (CPI) is still incomplete, restraining the achievement of full benefit from CPI.OBJECTIVES: We studied peripheral T cell turnover and evolution and their prognostic value after 3weeks on treatment with CPI (one cycle) analysing T cell receptor-β (TCR) sequences in plasma cell-free DNA (cfDNA) and PBMC, and performing a phenotypic analysis of peripheral T cell subsets.RESULTS: Peripheral T cell turnover and TCR repertoire dynamics correlated with response. Additionally, the cfDNA TCR repertoire reorganisation fingerprint correlated with the expansion of an immune-effector subset of peripheral T cells that predicted treatment response and identified the patients with longer overall survival.CONCLUSIONS: Here we show that prognostic changes in peripheral T cells occur within 3 weeks of commencing CPI treatment. This dynamic immune-awakening informs on the immune-system reorganization can be monitored using minimally invasive liquid biopsies.","dates":{"updated":"2022-03-04 18:10:04"},"accession":"EGAS00001004043","cross_references":{"TAXONOMY":["9606"],"EGA":["EGAD00001005747","EGAC00001000514"]}}